Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically confirmed primary cutaneous T-cell lymphoma (CTCL)~2. Age ≥ 18 years~3. Performance status WHO\<=2~4. Subject must have adequate bone marrow, renal and hepatic function~5. Topical and phototherapy treatment failure in the past~6. Signed informed consent~Exclusion Criteria:~1. Subject has received prior systemic methotrexate or interferon therapy~2. Unacceptable methotrexate or interferon treatment toxicity in the past~3. Inadequate bone marrow, renal or hepatic function as follows:~   * Bone Marrow: Absolute neutrophil count (ANC) \< 1,500/mm 3 (1.5 × 10 9 /L); Platelets \<100,000/mm 3 (100 × 10 9 /L); Hemoglobin \< 9.0 g/dL (1.4 mmol/L);~  * Renal function: Creatinine \>1.5 x Upper limit of normal (ULN)~  * Hepatic function: Aspartate and Alanine transaminase (AST and ALT) \>3× ULN; bilirubin \> 1.5 × ULN~  * Active hepatitis B or hepatitis C~4. anorexia~5. major depression with suicidal ideation or suicide attempt in the past~6. Symptomatic congestive heart failure~7. Epilepsia or other symptomatic central nervous system dysfunction~8. active skin infection not related to underlying CTCL, active Tuberculosis, HIV infection~9. Subject is pregnant or lactating~10. Psychiatric illness/social situation that would limit compliance with study requirements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Methotrexate arm (Type: ACTIVE_COMPARATOR): Patients assigned to receive methotrexate
- Interferon Alfa-2b (Type: ACTIVE_COMPARATOR): Patients assigned to receive Interferon alfa 2b

Based on this trial design, predict the completion outcome and termination type (if applicable).